CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA

Minesh Mehta; Rupesh Kotecha; Yazmin Odia

CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA

Minesh Mehta, Rupesh Kotecha, Yazmin Odia

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 1 2020
Event	Neuro-Oncology - Duration: Sep 8 2023 → …

Conference

Conference	Neuro-Oncology
Period	9/8/23 → …

Cite this

@conference{a13a2bed84f34fd78ade0d43a280c36a,

title = "CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA",

author = "Minesh Mehta and Rupesh Kotecha and Yazmin Odia",

note = "Neuro-Oncology (2020) 22(Supplement_2):ii36-ii36; Neuro-Oncology ; Conference date: 08-09-2023",

year = "2020",

month = nov,

day = "1",

language = "American English",

}

TY - CONF

T1 - CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA

AU - Mehta, Minesh

AU - Kotecha, Rupesh

AU - Odia, Yazmin

N1 - Neuro-Oncology (2020) 22(Supplement_2):ii36-ii36

PY - 2020/11/1

Y1 - 2020/11/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3938

M3 - Presentation

T2 - Neuro-Oncology

Y2 - 8 September 2023

ER -

CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA

Conference

Other files and links

Cite this